Risk Factors for Acute Kidney Injury in Acute Pancreatitis: A 7-year Retrospective Analysis of Patients in a Large Tertiary Hospital

CURRENT STATUS: UNDER REVIEW

Bingjun Yu  
First Affiliated Hospital of Nanchang University

Wenhua He  
First Affiliated Hospital of Nanchang University

Nonghua Lu  
First Affiliated Hospital of Nanchang University

✉ lunonghua@ncu.edu.cn Corresponding Author
ORCiD: https://orcid.org/0000-0003-4373-551X

DOI: 10.21203/rs.3.rs-17634/v1

SUBJECT AREAS  
Gastroenterology & Hepatology

KEYWORDS  
hypertriglyceridaemia, severity, acute kidney injury, acute pancreatitis, risk factor, organ failure
Abstract
Background Acute kidney injury (AKI) is a serious complication of acute pancreatitis (AP) and causes a high risk of mortality. The aim of this study was to investigate the risk factors for AKI in patients in the early phase of AP.

Methods In this retrospective observational study, 1655 AP patients were divided into an AKI and a non-AKI group. Age, sex, BMI, APACHE II score, smoking history, hypertriglyceridaemia (HTG), alcohol abuse, biliary disease, organ failure, pancreatic necrosis and necrosis debridement were collected from the hospital record database.

Results 1036 males (62.6%) and 619 females (37.4%) were enrolled in this study. 1255 and 430 AP patients were included in the non-AKI and AKI groups, respectively. The mean age was 45.90±11.73 years. Hospital and intensive care unit (ICU) lengths of stay were 18.13±43.26 and 31.53±72.47 days, respectively. The incidence of organ failure and pancreatic necrosis were 25.0% and 32.2%, respectively. The morbidity of percutaneous catheter drainage (PCD) and operative necrosectomy (ON) was 10.9%, and the mortality among AP patients was 6.3%. HTG was identified as a risk factor for AKI in AP (P=0.001). The incidence of organ failure (P=0.001), pancreatic necrosis (P=0.001) and necrosis debridement were greater in the AKI group than those in the non-AKI group.

Conclusions HTG is an independent risk factor for AKI in AP. AP patients with AKI have adverse outcomes such as high rates of organ failure, pancreatic necrosis, and necrosis debridement and longer hospital and ICU lengths of stay.

Background
Acute pancreatitis (AP) is characterized by oedema, haemorrhage and necrosis caused by various mechanisms and is a potentially life-threatening disease due to the risk of organ failure [1, 2]. A study proposed that 20–25% of AP patients develop acute kidney injury (AKI), and that the total mortality among AP patients with AKI is nearly 25% [3, 4]. Thus, managing AP patients with AKI remains challenging. The pathogenesis and the exact mechanism of AP with AKI may involve the following processes: Firstly, cytokine cascades caused by systemic inflammatory response syndrome (SIRS) in the early phase of AP lead to the development of AKI [5–7]. Secondly, endotoxins and reactive oxygen
species (ROS) also play key roles in the pathophysiology of AKI in AP patients. Thirdly, serum phospholipase A2 (PLA2) activity is related to renal tubular cell injury in AP patients [8–10]. All the above pathological processes of AKI may aggravate AP progression. Therefore, we hypothesized that identifying possible risk factors for AKI in AP patients can substantially reduce the complication and mortality rates associated with the disease.

To date, many studies [10] have proposed that hypoxaemia, a history of renal disease, abdominal compartment syndrome, and other conditions are associated with AKI in AP patients. However, the risk factors for the development of AKI in the early phase of AP have not been well defined. Thus, the causal relationships between such risk factors and AKI in AP patients must be investigated.

In general, AKI may emerge within a few hours after AP onset, and cytokines act as triggers in the course of AKI in AP [11]. The seriousness of AKI in AP patients cannot be overlooked. Obesity, diabetes, body mass index (BMI) and hypertriglyceridaemia (HTG) are often complicated by AP and are closely related to renal diseases [12–14]. Hence, the relationship between these factors and AKI in AP patients is a reasonable consideration.

The aims of our study were to verify risk factors in the early phase of AP-related AKI and to clarify the relationship between prognostic factors and AKI based on prospectively collected AP patient data.

**Methods**

**Patient data**

This was a large retrospective study with patient data from the AP database of the First Affiliated Hospital of Nanchang University, which was approved by the ethics committee (database approval number: 2011001). From January 1, 2012, to December 31, 2018, 1655 patients who presented with AP were identified in our AP database in the department of digestion of the First Affiliated Hospital of Nanchang University. Patients younger than 18 years or older than 80 years was excluded from the study. The exclusion criteria are listed in Figure 1. We recorded clinical data such as age, sex, a history of smoking and drinking alcohol, diabetes, hypertension, a history of renal diseases, complications, the severity of AP during hospitalization, death, the length of stay in hospital after AP onset and body mass index (BMI) on admission. Weight in kilograms divided by height in square
metres was measured as the BMI (kg/m\(^2\)). Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated based on patient data.

**Diagnosis and definitions**

The total population was divided into two groups: the AKI group and the non-AKI group. The early phase of AP with AKI was defined as within 7 d after AP onset. AKI was defined as an absolute increase in serum creatinine greater than 0.3 mg/dl (≥26.4 μmol/l) and a percentage increase in serum creatinine greater than 50% (1.5-fold from baseline) within 48 hours [15]. AP was diagnosed based on the 2012 revised Atlanta classification criteria [11]. Biliary disease was defined as 1 or more gallstones or bile duct dilation and laboratory results indicative of obstructive jaundice [16], alcohol abuse was defined as the consumption of more than 80 g of alcohol per day for at least 5 years [17,18], and HTG was defined as a serum Triglyceride(TG) level on admission greater than 11.3 mmol/L or greater than 5.65 mmol/L with lactescent serum before AP onset [18,19]. The 2012 revision of the Atlanta Acute Pancreatitis Diagnostic and Classification Criteria was used to classify AP severity. Organ failure was defined according to the modified Marshall Scoring System [11]. Pancreatic necrosis was diagnosed by contrast-enhanced computed tomography (CECT) based on diffuse enlargement of the pancreatic or peripancreatic volume, blurred edges surrounding the pancreas, mild enhancement of the oedema area after enhanced scanning, and no enhancement of necrotic areas [20,21]. Mortality was defined as death during hospitalization. These definitions are shown in Supplementary table 1.

**Statistical analyses**

Statistical comparisons of the two groups were performed using the \(\chi^2\) test. \(P < 0.05\) was considered statistically significant and two-tailed Fisher’s exact test was used. SPSS version 21 was used for all analyses. We expressed continuous variables as the mean (SEM) or as the median with the interquartile range, and normally distributed data were analysed by a 2-tailed t test, whereas non-normally distributed data were tested by the Mann-Whitney U test. Risk factors and odds ratios (ORs) were examined using multivariate logistic regression analysis. Subsequently, variables with a \(P\) value < 0.2 on univariate analysis were entered into a multivariable Cox regression to identify independent
Results

Baseline characteristics of the patients

A total of 1655 patients were admitted within 72 hours of AP onset and 1225 patients were included in the non-AKI group, while 430 patients were included in the AKI group. Overall, 1036 males (62.6%) and 619 females (37.4%) were enrolled. The mean age of all the AP patients was 45.90±11.73 years. The hospital length of stay (18.13±43.26 vs 31.53±72.47 days) and intensive care unit (ICU) length of stay (0.87±3.78 vs 7.63±14.16 days) in days in the AKI group were longer than those in the non-AKI group (P=0.001). The incidence rates of organ failure and pancreatic necrosis were 25.0% and 32.2%, respectively. The morbidity rate of percutaneous catheter drainage (PCD) and operative necrosectomy (ON) was 10.9%, and the mortality rate among the AP patients was 6.3%. Detailed data of the patients’ conditions are listed in Tables 1, 2, 3 and 4.

APACHE II scores (6.75±4.24 in the non-AKI group vs 9.16±5.54 in the AKI group) and the severity of AP differed between the non-AKI group and the AKI group, as shown in Supplementary table 2. A total of 196 patients (45.7%) developed AKI in the first 24 h, 111 patients (25.9%) were diagnosed with AKI in the following 24 hours, and 122 patients (28.4%) developed AKI on the third day. These details are listed in Supplementary table 3.

Risk factors among the AP patients with AKI

In the univariate analysis, 5 factors had a P value < 0.2, including age (OR, 1.000; 95% confidence interval [CI], 1.000-1.001; P=0.115), BMI (OR, 1.007; 95%CI, 0.999-1.105, P=0.109), diabetes (OR, 1.279; 95%CI, 0.930-1.758, P=0.131), HTG (OR, 7.715; 95%CI, 5.792-9.493, P=0.001) and biliary diseases (OR, 1.270; 95%CI, 1.212-1.344, P=0.001). These 5 risk factors were subjected to multivariate logistic regression analysis. The P values showed that HTG (OR, 6.556; 95%CI, 4.817-8.923, P=0.001) was a significant risk factor for AP with AKI. Detailed data of the patients’ conditions are listed in Tables 1 and 2.

The incidence rates of complications and debridement of necrosis among the AP patients

Univariate and multivariate logistic regression analyses were applied to AP complications and the
results showed that AP patients with AKI experienced more complications and required more interventions. In the multivariate logistic regression analyses, the P value for organ failure, pancreatic necrosis and debridement of necrosis was 0.001 (OR, 17.605; 95%CI, 11.828-26.205), 0.001 (OR, 2.276; 95%CI, 1.539-3.366) and 0.001 (OR, 2.286; 95%CI, 1.701-4.761) respectively. Detailed patient data are listed in Tables 3 and 4.

The incidence of mortality among the AP patients

The mortality of AP was also examined by logistic regression analysis. The results showed no significant difference in mortality between the AKI and non-AKI groups (OR, 1.150; 95%CI, 0.651-2.029; P=0.631), as shown in Table 4.

Discussion

The AP has a wild range of mortality depending on its severity. AKI is one of the most common complications in AP patients and have a dramatic impact on clinical outcome in the course of AP. AKI is known to often occur in the early phase of AP, especially within the first week of AP onset and is closely related to increased mortality rate, costs and days of hospitalization. In this study, the results shows that most AKIs are diagnosed within the first 48 hours, and the injury of renal function is even earlier. As most patients have experienced AKI on admission, it is necessary for us to investigate the predictive factors for AKI in the early phase of AP.

In previous study, HTG was proposed to be an aetiological factor of AP several years ago [22–24] and HTG-associated AP is a potentially fatal disease with high mortality and complication rates [25]. Although the exact pathogenesis of HTG-associated AP is not clearly defined, it may be associated with toxic damage to acinar cells [26, 27]. The contribution of HTG to all AP aetiologies varies in different studies. Twenty years ago, Fortson et al. reported that HTG accounted for 1.3–3.8% of the aetiology of AP [28], while a multi-centre study in Taiwan showed that HTG-associated AP accounted for 12.3% of all AP cases [29]. Another study performed by Jieshou Li also reported that HTG is a risk factor for AP [30], and that the different range of HTG may be related to the outcomes in the early phase of AP with AKI [31]. An animal experimental model of AP also showed that high levels of HTG in mice (ApoCIIIgt) can accelerate kidney damage during the course of AP, especially severe HTG levels
The above studies indicate that HTG is an important risk factor when predicting the occurrence of AKI in AP patients and plays a critical role in influencing the progression of AP. These results are similar to those in our study indicating that HTG is an independent risk factor for AKI in the early phase of AP, with a prevalence of HTG of 38.3% among the entire population and a prevalence as high as 49.2% in the AKI group.

Although HTG is a well-recognized cause of AP, it is not responsible for all these patients as etiology. Havel reported that a high level of free fatty acids (FFAs) is a potential cause for AP, which is caused by the hydrolysis of TG by pancreatic lipase. We hypothesize that the mechanism of AKI development in the early phase of AP involves the following processes: Pancreatic lipase hydrolyses excess TG in serum, leading to the accumulation of FFAs, which are damaging to organ function. The FFAs may directly impair the renal parenchyma and cause high levels of pancreatic enzymes in the glomerulus, which can lead to aggravation of renal function damage. This mechanism can explain why HTG accounts for a substantial proportion of AP cases with AKI and why AKI occurs very early in most cases. This hypothesis can explain why hypertriglyceridemia takes a great proportion of patients with AKI and why AKI occurs so early in most cases.

The AP patients with HTG may have chronic kidney disease such as glomerulosclerosis. This is a neglected problem as relevant tests are seldom taken when AP is the primary illness. We suppose that patients presenting with AKI in the early phase of AP have a special physiology that can be described as a “time bomb”, then leads to the progression of AP. Pre-existing metabolic disorders such as diabetes, chronic kidney disease and hypertension are responsible for the severity of AP. Hence, identifying AP patients with a high risk for AKI is important. Physicians should focus more on risk factors in AP patients.

The role of HTG in governing the course of AP is controversial. In recent years, studies have shown that HTG is related to the severity of AP and accentuates acute necrotizing pancreatitis. In our study, we also found that HTG was an independent risk factor for AKI in AP patients and aggravated the severity of the disease and pancreatic necrosis. The revised Atlanta classification indicates that cytokine cascades resulting in SIRS are established during the development of organ
failure of AKI in AP patients [11]. SAP begins with SIRS in the early phase, which is obviously significant in patients with organ failure. As it is very clear that cytokines are directly responsible for organ failure in SIRS and sepsis. it is reasonable to bring inflammation and organ failure together in SAP [5, 39, 40]. Our results may be a potential supplementary to this wildly accepted opinion of AKI in the early phase of AP.

The APACHE II is an assessment tool for AP that contains a variety of indicators, including creatinine and HTG. In clinical practice, APACHE II scores are often used as a general measure to evaluate AP. Study have evidenced that APACHE II scores can predict the severity of AP with 100% accuracy [41]. In this study, the results show that the APACHE II score in the AKI group was significantly higher than that in the non-AKI group. Hence, the APACHE II score may also reflect the severity of the AP with AKI. However, we should also collect SIRS scores and RANSON scores for comparison with APACHE II scores in future research.

A previous study reported that severe HTG is usually associated with high mortality in AP patients with AKI and reflects a poor prognosis. In our study, the mortality rate in the AKI group was higher than that in the non-AKI group [42, 43], but no significant different was found between the two groups. We speculated that the reasons for this finding are the small number of cases of mortality among the AP patients that difficult to establish statistical analysis. In addition, the AP patients with AKI usually had longer hospital stays and ICU stays in this study. More importantly, these patients also had higher rates of pancreatic necrosis and debridement of necrosis (PCD and/or ON). According to the above results, we know that AP patients with AKI can easily progress to a serious state. Therefore, It is important to identify patients with high risk for AKI. Physicians should pay more attention to patients with SAP.

Strengths And Limitations
This study has several strengths. This is the first large-sample study to explore risk factors for the development of AKI in the early phase of AP. Our data show that a change in HTG is an independent risk factor for AKI in AP. Finally, The results in this study provide good guidance for further clinical work.
Several limitations exist in this study. Firstly, this is a retrospective observational study which does not absolutely imply causality between HTG and AKI. Therefore, a prospective study is needed to address the role of HTG in AKI with AP patients. Secondly, There are a little bias of the results in this study because we excluded 281 patients with a history of diabetes, kidney disease, or hypertension which would substantially impact serum creatinine levels.

Conclusion
AKI is a complication of the early phase of AP and HTG is an independent risk factor for this complication. We speculate that accumulation of FFAs and cytokines in renal tissue may be an underlying mechanism. AP patients with AKI have adverse outcomes such as high rates of organ failure, pancreatic necrosis, and debridement of necrosis (PCD and/or ON) and long hospital and ICU stays.

Abbreviations
Hypertriglyceridaemia: HTG. Acute pancreatitis: AP. Reactive oxygen species: ROS. Acute kidney injury: AKI. Phospholipase A2: PLA2. Severe acute pancreatitis: SAP. Body mass index: BMI. Acute respiratory distress syndrome: ARDS. Odds ratio: OR. Confidence interval: CI. Mild acute pancreatitis: MAP. Moderate severe acute pancreatitis: MSAP. Wild-type: WT. Systemic inflammatory response syndrome: SIRS. Acute Physiology and Chronic Health Evaluation II: APACHE II. Intensive care unit: ICU

Declarations

Acknowledgments
We thank Dr. Wenhua He for helpful suggestions in data collection.

Authors’ contributions: YuBingjun conceived the study; Wenhua He and Nonghua Lu participated in the study design; YuBingjun collected the data; YuBingjun, Wenhua He performed the statistical analyses; YuBingjun drafted the manuscript; and Nonghua Lu edited and reviewed the manuscript. All of the authors have read and approved the final manuscript.

Funding
The study design and data collection were funded by the national natural science foundation of China: (No :81660114 and 81860122). The Key Research and Development Program from the Science and Technology Department of Jiangxi Province (No. 20192BBG70037).

Availability of data and materials: The data enrolled and analyzed in our study are not publicly available due to appropriate protection of patient personal information but are available from the
corresponding author on reasonable request.

Ethics approval and consent to participate: The study was approved by the ethics committee of the First Affiliated Hospital of Nanchang University (database approval number: 2011001) prior to data collection. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. This study is a retrospective analysis, it did not include any human trial, and as such no informed consent from patients was needed.

Consent for publication: Not applicable.

Competing interests: The authors declare no potential conflicts of interest. No writing assistance was provided in the production of this manuscript.

Patient and public involvement: Patients were not involved in the design of this research study.

Author details: 1 Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China. 2 Department of cardiothoracic surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China

References
1  Carr RA, Rejowski BJ, Cote GA, Pitt HA and Zyromski NJ. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? PANCREATOLOGY. 2016; 16(4):469-476.
2  Scherer J, Singh VP, Pitchumoni CS and Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J CLIN GASTROENTEROL. 2014; 48(3):195-203.
3  Lin HY, Lai JL, Lai YC, Lin PC, Chang SC and Tang GJ. Acute renal failure in severe pancreatitis: A population-based study. Ups J Med Sci. 2011; 116(2):155-159.
4  Hamada S, Masamune A and Shimosegawa T. Management of acute pancreatitis in Japan: Analysis of nationwide epidemiological survey. World J Gastroenterol. 2016; 22(28):6335-6344.
5  Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ and Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006; 93(6):738-744.
6 Buter A, Imrie CW, Carter CR, Evans S and McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg. 2002; 89(3):298-302.

7 Johnson CD and Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. GUT. 2004; 53(9):1340-1344.

8 Gronroos JM, Hietaranta AJ and Nevalainen TJ. Renal tubular cell injury and serum phospholipase A2 activity in acute pancreatitis. Br J Surg. 1992; 79(8):800-801.

9 Zhang XP, Zhang J, Ma ML, Cai Y, Xu RJ, Xie Q, Jiang XG and Ye Q. Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary Pancreat Dis Int. 2010; 9(1):83-87.

10 Esrefoglu M. Experimental and clinical evidence of antioxidant therapy in acute pancreatitis. World J Gastroenterol. 2012; 18(39):5533-5541.

11 Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG and Vege SS. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. GUT. 2013; 62(1):102-111.

12 Sadr-Azodi O, Orsini N, Andren-Sandberg A and Wolk A. Abdominal and total adiposity and the risk of acute pancreatitis: a population-based prospective cohort study. AM J GASTROENTEROL. 2013; 108(1):133-139.

13 Shen HN and Lu CL. Incidence, resource use, and outcome of acute pancreatitis with/without intensive care: a nationwide population-based study in Taiwan. PANCREAS. 2011; 40(1):10-15.

14 Huang X, Sjogren P, Arnlov J, Cederholm T, Lind L, Stenvinkel P, Lindholm B, Riserus U and Carrero JJ. Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease. J INTERN MED. 2014; 275(1):71-83.

15 Ozcakar ZB, Yalcinkaya F, Altas B, Ergun H, Kendirli T, Ates C, Elhan AH and Ekim M. Application of the new classification criteria of the Acute Kidney Injury Network: a pilot study in a pediatric population. PEDIATR NEPHROL. 2009; 24(7):1379-1384.

16 van Santvoort HC, Bakker OJ, Besselink MG, Bollen TL, Fischer K, Nieuwenhuijs VB, Gooszen HG and Erpecum KJ. Prediction of common bile duct stones in the earliest stages of acute biliary
pancreatitis. ENDOSCOPY. 2011; 43(1):8-13.

17 Gullo L, Migliori M, Olah A, Farkas G, Levy P, Arvanitakis C, Lankisch P and Beger H. Acute pancreatitis in five European countries: etiology and mortality. PANCREAS. 2002; 24(3):223-227.

18 Lloret LC, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, Ruszniewski P and Bruckert E. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. PANCREAS. 2008; 37(1):12-13.

19 Consensus conference: Treatment of hypertriglyceridemia. JAMA. 1984; 251(9):1196-1200.

20 Dellinger EP, Forsmark CE, Layer P, Levy P, Maravi-Poma E, Petrov MS, Shimosegawa T, Siriwardena AK, Uomo G, Whitcomb DC and Windsor JA. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. ANN SURG. 2012; 256(6):875-880.

21 Li W, Zhang L, Li J, Dellinger EP, Forsmark CE, Layer P, L'Evy P, Poma EM, Petrov MS, Shimosegawa T, Siriwardena AK, Uomo G, Whitcomb DC and Windsor JA. [Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation: the 2013 Chinese edition]. Zhonghua Wai Ke Za Zhi. 2014; 52(5):321-324.

22 Dominguez-Munoz JE, Junemann F and Malfertheiner P. Hyperlipidemia in acute pancreatitis. Cause or epiphenomenon? Int J Pancreatol. 1995; 18(2):101-106.

23 Yuan G, Al-Shali KZ and Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176(8):1113-1120.

24 Havel RJ. Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med. 1969; 15:117-154.

25 Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG and Eugenidis NP. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J CLIN GASTROENTEROL. 2002; 34(4):472-475.

26 Saharia P, Margolis S, Zuidema GD and Cameron JL. Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas. SURGERY. 1977; 82(1):60-67.

27 Kimura W and Mossner J. Role of hypertriglyceridemia in the pathogenesis of experimental
acute pancreatitis in rats. Int J Pancreatol. 1996; 20(3):177-184.

28 Fortson MR, Freedman SN and Webster PR. Clinical assessment of hyperlipidemic pancreatitis. AM J GASTROENTEROL. 1995; 90(12):2134-2139.

29 Deng LH, Xue P, Xia Q, Yang XN and Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008; 14(28):4558-4561.

30 Wu C, Ke L, Tong Z, Li B, Zou L, Li W, Li N and Li J. Hypertriglyceridemia is a risk factor for acute kidney injury in the early phase of acute pancreatitis. PANCREAS. 2014; 43(8):1312-1316.

31 Wu C, Zou L, Shi S, Tong Z, Shen X, Yang D, Ke L, Li W and Li J. The role of hypertriglyceridemia for acute kidney injury in the course of acute pancreatitis and an animal model. PANCREATEOLOGY. 2017; 17(4):561-566.

32 Wu C, Zou L, Shi S, Tong Z, Shen X, Yang D, Ke L, Li W and Li J. The role of hypertriglyceridemia for acute kidney injury in the course of acute pancreatitis and an animal model. PANCREATEOLOGY. 2017; 17(4):561-566.

33 Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M and Ditschuneit H. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol. 1991; 10(3-4):261-267.

34 Yadav D and Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J CLIN GASTROENTEROL. 2003; 36(1):54-62.

35 Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeny P, Imrie C and Tandon R. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol. 2002; 17 Suppl:S15-S39.

36 Chang MC, Su CH, Sun MS, Huang SC, Chiu CT, Chen MC, Lee KT, Lin CC and Lin JT. Etiology of acute pancreatitis--a multi-center study in Taiwan. Hepatogastroenterology. 2003; 50(53):1655-1657.

37 Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M and Ditschuneit H. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol. 1991; 10(3-4):261-267.

38 Navarro S, Cubiella J, Feu F, Zambon D, Fernandez-Cruz L and Ros E. [Hypertriglyceridemic
acute pancreatitis. Is its clinical course different from lithiasic acute pancreatitis?). Med Clin (Barc). 2004; 123(15):567-570.

39 Mayerle J, Dummer A, Sendler M, Malla SR, van den Brandt C, Teller S, Aghdassi A, Nitsche C and Lerch MM. Differential roles of inflammatory cells in pancreatitis. J Gastroenterol Hepatol. 2012; 27 Suppl 2:47-51.

40 Zarjou A and Agarwal A. Sepsis and acute kidney injury. J AM SOC NEPHROL. 2011; 22(6):999-1006.

41 Ji CL, Zhou HR, Peng CH, Yang XL and Zhang Q. [Comparison of value of GRACE, APACHEII and REMS for early prognosis of death in patients with acute myocardial infarction]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013; 25(11):660-663.

42 Navina S, Acharya C, DeLany JP, Orlichenko LS, Baty CJ, Shiva SS, Durgampudi C, Karlsson JM, Lee K, Bae KT, Furlan A, Behari J, Liu S, McHale T, Nichols L and Papachristou GI, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. SCI TRANSL MED. 2011; 3(107):107r-110r.

43 Abhyankar S, Leishear K, Callaghan FM, Demner-Fushman D and McDonald CJ. Lower short- and long-term mortality associated with overweight and obesity in a large cohort study of adult intensive care unit patients. CRIT CARE. 2012; 16(6):R235.

Tables

Table 1. The basic characteristics of the study population
|                          | All patients N=16 | Non-AKI (N=1225) | AKI (N=430) | P value |
|--------------------------|-------------------|------------------|-------------|---------|
| Age                      | 45.90±11.73       | 45.89±11.76      | 45.92±11.68 | 0.96<sup>a</sup> |
| **Sex**                  |                   |                  |             |         |
| Male                     | 1036(62.6%)       | 768(62.7%)       | 268(62.3%)  | 0.908<sup>b</sup> |
| Female                   | 619(37.4%)        | 457(37.3%)       | 162(37.7%)  |         |
| **BMI**                  | 24.67±12.60       | 24.35±10.72      | 25.60±16.84 | 0.079<sup>a</sup> |
| **Diabetes**             |                   |                  |             |         |
| Yes                      | 208(12.6%)        | 145(11.8%)       | 63(14.7%)   | 0.078<sup>b</sup> |
| No                       | 1447(87.4%)       | 1080(88.2%)      | 367(85.3%)  |         |
| **Biliary disease**      |                   |                  |             |         |
| Yes                      | 840(50.8%)        | 701(57.2%)       | 114(26.5%)  | 0.001<sup>b</sup> |
| No                       | 815(49.2%)        | 524(42.8%)       | 316(73.5%)  |         |
| **Alcohol abuse**        |                   |                  |             |         |
| Yes                      | 384(23.2%)        | 278(22.7%)       | 106(24.7%)  | 0.408<sup>b</sup> |
| No                       | 1271(76.8%)       | 947(77.3%)       | 324(75.3%)  |         |
| **Hypertriglyceridaemia**|                   |                  |             |         |
| Yes                      | 634(38.3%)        | 322(26.3%)       | 312(72.6%)  | 0.001<sup>b</sup> |
| No                       | 1021(61.7%)       | 903(73.7%)       | 118(27.4%)  |         |
| **Hypertension**         |                   |                  |             |         |
| Yes                      | 304(18.4%)        | 228(18.6%)       | 76(17.7%)   | 0.718<sup>b</sup> |
| No                       | 1351(81.6%)       | 997(81.4%)       | 354(82.3%)  |         |
| **History of renal diseases** |             |                  |             |         |
| Yes                      | 161(9.7%)         | 112(9.1%)        | 49(11.4%)   | 0.337<sup>b</sup> |
| No                       | 1493(90.2%)       | 1112(90.9%)      | 381(88.6%)  |         |
| **History of smoking**   |                   |                  |             |         |
| Yes                      | 364(22.0%)        | 269(22.0%)       | 95(22.1%)   | 0.946<sup>b</sup> |
| No                       | 1291(78.0%)       | 956(78.0%)       | 335(77.9%)  |         |

Note * a: t test, comparison between the training group and validation group; b: Chi-squared test, comparison between the training group and validation group.

Abbreviations: AKI, Acute kidney injury; PCD, Percutaneous catheter drainage; ON, Operative necrosectomy.

Table 2. Univariate and multivariate Cox regression analyses of risk factors in AP patients
| Variable                  | Univariate analysis |        | Multivariate analysis |        |
|--------------------------|---------------------|--------|-----------------------|--------|
|                          | OR (95%CI)          | P value| OR (95%CI)            | P value|
| Age                      | 1.000(1.000-1.001)  | 0.115  | 1.009(0.998-1.020)    | 0.01   |
| Sex                      |                     |        |                       |        |
| Male                     | Reference           |        |                       |        |
| Female                   | 1.016(0.810-1.274)  | 0.892  |                       |        |
| BMI                      | 1.007(0.999-1.015)  | 0.109  | 1.005(0.997-1.014)    | 0.24   |
| Diabetes                 |                     |        |                       |        |
| No                       | Reference           |        |                       |        |
| Yes                      | 1.279(0.930-1.758)  | 0.131  | 1.369(0.960-1.953)    | 0.08   |
| Biliary disease          |                     |        |                       |        |
| No                       | Reference           |        |                       |        |
| Yes                      | 1.270(1.212-1.344)  | 0.001  | 0.794(0.576-1.094)    | 0.15   |
| Alcohol abuse            |                     |        |                       |        |
| No                       | Reference           |        |                       |        |
| Yes                      | 1.114(0.862-1.441)  | 0.408  | 0.900(0.676-1.199)    | 0.47   |
| Hypertriglyceridaemia    | Yes                 |  7.715(5.792-9.493) |  0.001 | 6.556(4.817-8.923) |  0.001 |
| Hypertension             | No                  | 0.939(0.703-1.253) | 0.668  |                       |        |
| History of renal diseases| No                  | Reference |        |                       |        |
| Yes                      | 0.986(0.920-1.056)  | 0.688  |                       |        |
| History of smoking       | No                  | Reference |        |                       |        |
| Yes                      | 1.008(0.773-1.314)  | 0.954  |                       |        |

Table 3. Characteristics of the patients: complications, interventions, stay time, and death

|                                      | All patients(n=1655) | Non-AKI (n=1225) | AKI (n=430) | P value |
|--------------------------------------|----------------------|------------------|-------------|---------|
| Organ failure (ARDS and/or shock)    |                      |                  |             |         |
| Yes                                  | 413(25.0%)           | 90(7.3%)         | 322(74.9%)  | 0.001b  |
| No                                   | 1242(75.0%)          | 1135(92.7%)      | 108(25.1%)  |         |
| Pancreatic necrosis                  |                      |                  |             |         |
| Yes                                  | 533(32.2%)           | 211(17.2%)       | 107(24.9%)  | 0.001b  |
| No                                   | 1122(67.8%)          | 1014(82.8%)      | 323(75.1%)  |         |
| Debridement of necrosis (PCD and/or ON) |                    |                  |             |         |
| Yes                                  | 181(10.9%)           | 42(3.4%)         | 139(32.3%)  | 0.001b  |
| No                                   | 1474(89.1%)          | 1183(96.6%)      | 291(67.7%)  |         |
| Mortality                            |                      |                  |             |         |
| Yes                                  | 104(6.3%)            | 29(2.4%)         | 75(17.4%)   | 0.001b  |
| No                                   | 1551(93.7%)          | 1196(97.6%)      | 355(82.6%)  |         |
| Hospital length of stay in days      | 21.61±52.8           | 18.13±43.26      | 31.53±72.47 | 0.001a  |
| ICU length of stay in days           | 2.62±8.45            | 0.87±3.78        | 7.63±14.16  | 0.001a  |

Note * a: t test, comparison between the training group and validation group; b: Chi-squared test, comparison between the training group and validation group.

Abbreviations: AKI, Acute kidney injury; PCD, Percutaneous catheter drainage; ON, Operative necrosectomy; ARDS, Acute respiratory distress syndrome.
Table 4. Univariate and multivariate Cox regression analyses of prognostic factors in AP patients

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | OR (95%CI)          | P value               | OR (95%CI)          | P value               |
| **Organ failure (ARDS and/or shock)**         |                     |                       |                      |                       |
| No                                            | Reference           |                       | Reference           |                       |
| Yes                                           | 38.069(28.023-51.716)| 0.001                 | 17.605(11.828-26.205)| 0.001                 |
| **Pancreatic necrosis**                       |                     |                       |                      |                       |
| No                                            | Reference           |                       | Reference           |                       |
| Yes                                           | 14.328(11.008-18.650)| 0.001                 | 2.276(1.539-3.366)  | 0.001                 |
| **Debridement of necrosis (PCD and/or ON)**   |                     |                       |                      |                       |
| No                                            | Reference           |                       | Reference           |                       |
| Yes                                           | 13.454(9.310-19.442)| 0.001                 | 2.286(1.701-4.761)  | 0.001                 |
| **Mortality**                                 |                     |                       |                      |                       |
| No                                            | Reference           |                       | Reference           |                       |
| Yes                                           | 8.713(5.585-13.592) | 0.001                 | 1.150(0.651-2.029)  | 0.631                 |
| **Hospital length of stay in days**           | 1.005(1.002-1.007)  | 0.001                 |                      |                       |
| **ICU length of stay in days**                | 1.206(1.168-1.244)  | 0.001                 |                      |                       |

Figures

![Study flowchart](image)

Figure 1

Study flowchart

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Supplemental Tables.docx
